株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

核医学/ラジオアイソトープ(放射性同位体)の世界市場:成長、動向、および予測(2019年~2024年)

Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 661020
出版日 ページ情報 英文 100 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.91円で換算しております。
Back to Top
核医学/ラジオアイソトープ(放射性同位体)の世界市場:成長、動向、および予測(2019年~2024年) Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年12月01日 ページ情報: 英文 100 Pages
概要

当レポートは世界の核医学/ラジオアイソトープ(放射性同位体)市場について調査しており、市場機会や動向、成長および阻害要因、ラジオアイソトープの種類・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 成長要因
    • 癌および心疾患の発生率の上昇
    • 核医学の幅広い用途
    • SPECTおよびPETでの用途増加
    • ヘルスケアに対する患者の意識の向上
  • 阻害要因
    • 償還の合併症
    • 規制の問題
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメンテーション

  • ラジオアイソトープの種類別
    • テクネチウム-99m(Tc-99m)
    • タリウム-201(Tl-201)
    • ヨウ素(I-123)
    • フッ素-18
    • ルビジウム-82(Rb-82)
    • ヨウ素-131(I-131)
    • ルテチウム-177(Lu-177)
    • ラジウム-223(Ra-223)・アルファラジン
    • アクチニウム-225(Ac-225)
    • その他
  • 用途別
    • 腫瘍
    • 循環器
    • リンパ腫
    • 甲状腺
    • 神経
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他

第6章 競合情勢

  • 企業プロファイル
    • Agfa-Gevaert Group
    • Cardiarc Ltd
    • Digirad Corporation
    • CMR Naviscan (Gamma Medica Inc.)
    • GE Healthcare
    • Positron Corp.
    • Segami Corporation
    • Siemens Healthcare GmBH
    • Nordion (Canada) Inc.
    • NTP Radioisotopes SOC Ltd
    • Bracco SpA
    • Cardinal Health Inc.
    • Curium

第7章 市場機会および今後の動向

目次
Product Code: 54625

Market Overview

Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicines radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves' disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.

Scope of the Report

As per the scope of the report, medical radioisotopes are defined as safe radioactive substances that are primarily used in the diagnosis of medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt, since the rays can decay as soon as the imaging is completed.

Key Market Trends

Oncology Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.

North America captured the Largest Market Share and is Expected to Retain its Dominance

North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America, and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.

Competitive Landscape

There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Cancer and Cardiac Disorders
    • 4.2.2 Widening Applications of Nuclear Medicine
    • 4.2.3 Increasing SPECT and PET Applications
    • 4.2.4 Increasing Patient Awareness for Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Complications
    • 4.3.2 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type of Radioisotopes
    • 5.1.1 Technetium-99m (Tc-99m)
    • 5.1.2 Thallium-201 (Tl-201)
    • 5.1.3 Iodine (I-123)
    • 5.1.4 Fluorine-18
    • 5.1.5 Rubidium-82 (Rb-82)
    • 5.1.6 Iodine-131 (I-131)
    • 5.1.7 Lutetium-177 (Lu-177)
    • 5.1.8 Radium-223 (Ra-223) & Alpharadin
    • 5.1.9 Actinium-225 (Ac-225)
    • 5.1.10 Others
  • 5.2 Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Lymphoma
    • 5.2.4 Thyroid
    • 5.2.5 Neurology
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agfa-Gevaert Group
    • 6.1.2 Cardiarc Ltd
    • 6.1.3 Digirad Corporation
    • 6.1.4 CMR Naviscan (Gamma Medica Inc.)
    • 6.1.5 GE Healthcare
    • 6.1.6 Positron Corp.
    • 6.1.7 Segami Corporation
    • 6.1.8 Siemens Healthcare GmBH
    • 6.1.9 Nordion (Canada) Inc.
    • 6.1.10 NTP Radioisotopes SOC Ltd
    • 6.1.11 Bracco S.p.A
    • 6.1.12 Cardinal Health Inc.
    • 6.1.13 Curium

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top